Effects of hydromorphone for patient-controlled intravenous analgesia on postpartum depression and sleep disorders after cesarean section: a randomized, double-blind controlled trial

Background: Postpartum depression (PPD) is a significant concern in obstetrics. This study aimed to investigate the effects of hydromorphone in patient-controlled intravenous analgesia (PCIA) on PPD and sleep disorders following cesarean section. Methods: A total of 140 parturients undergoing elective cesarean section under combined spinal-epidural anesthesia, with singleton full-term pregnancy and aged 22-35 years, were enrolled from July to December 2025 at Jiangning Hospital Affiliated to Nanjing Medical University. Using a random number table, participants were allocated to two groups based on PCIA formulation: the sufentanil group (Group S) received sufentanil (3 μg/kg) + tropisetron (0.1 mg/kg) diluted to 150 mL with normal saline; the hydromorphone group (Group H) received hydromorphone (0.15 mg/kg) + tropisetron (0.1 mg/kg) diluted to 150 mL with normal saline. The primary outcome was the incidence of PPD at 6 weeks postoperatively. Secondary outcomes included PPD incidence at 1 week, Ramsay sedation scores at 24 and 48 h, Pittsburgh Sleep Quality Index (PSQI) scores preoperatively and at 24/48 h, resting Visual Analog Scale (VAS) pain scores at 6, 12, 24, and 48 h, PCIA button presses and rescue analgesia within 48 h, cumulative 48-hour opioid consumption, bowel function recovery time, first lactation time, neonatal behavioral neurological assessment (NBNA) scores at 48 h postoperatively and adverse reactions. Results: < 0.01). No significant intergroup differences were found in analgesia-related outcomes or other adverse reactions. Conclusion: Hydromorphone for PCIA after cesarean section can reduce the incidence of PPD at 6 weeks, improve early postoperative sleep quality, and decrease dizziness and drowsiness. Clinical Trial Registration: https://www.chictr.org.cn/bin/home, identifier ChiCTR2500105264.